Is Wegovy Better Than Ozempic for Weight Loss?

The biggest myth: Ozempic and Wegovy are the same thing

It is easy to see why people conflate them. Both contain semaglutide. Both are made by Novo Nordisk. Both are once-weekly subcutaneous injections. On those facts alone, the idea that one is simply a rebranded version of the other sounds plausible.

But UK medicines licensing is more specific than that. The MHRA licenses a medicine for defined indications at defined doses. The NHS's semaglutide guidance is clear: Ozempic is licensed for type 2 diabetes management in the UK. Wegovy is licensed for weight management, at a higher maintenance dose of 2.4mg weekly, compared with Ozempic's 1mg or 0.5mg diabetes doses. Prescribing Ozempic to someone without type 2 diabetes for the purpose of losing weight would be off-label use, which is a clinical and regulatory decision that a prescriber would need to justify individually. It is not a route nume offers, and it is not something any regulated UK pharmacy should be doing routinely.

So when people ask whether Ozempic is better than Wegovy, they are usually asking the wrong question. The right question is whether semaglutide, via Wegovy at the correct licensed dose and indication, is genuinely the better option compared with Ozempic, and that is what a prescriber is there to answer. You can read more about how the two products compare in detail on our Wegovy vs Ozempic overview.

What the trial data shows for Wegovy, and why dose matters

Wegovy's evidence base is substantial. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. Participants on semaglutide 2.4mg saw an average body-weight reduction of around 15%, compared with roughly 2.4% on placebo, alongside lifestyle support. That is the dose Wegovy delivers.

Ozempic's diabetes doses (0.5mg and 1mg) produce meaningful weight reduction as a secondary effect in people with type 2 diabetes, but the magnitude is considerably smaller than 2.4mg. Dose drives efficacy with semaglutide: the higher the dose (within the licensed schedule), the greater the appetite suppression and weight reduction on average. Using an Ozempic pen as a weight-loss workaround is not the same as using Wegovy, even though the molecule is identical.

For a broader look at how semaglutide performs relative to other licensed options, this page explores what current evidence says about alternatives to Wegovy. And if you are weighing up whether semaglutide itself is the better choice compared with tirzepatide, our semaglutide comparison page works through that question in detail.

What is actually licensed for weight loss in the UK, and what nume prescribes

Two injectable medicines currently hold a UK marketing authorisation specifically for weight management: Wegovy (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly). Mounjaro is the only dual GIP and GLP-1 receptor agonist licensed here, it works on two gut-hormone pathways rather than one, which is why SURMOUNT-5 head-to-head data published in 2025 showed greater average weight reduction for tirzepatide than semaglutide 2.4mg over 72 weeks. You can explore how those two stack up on our treatment overview page.

Ozempic does not belong on that list. Neither does Saxenda (liraglutide), which is licensed for weight management but not dispensed by nume, our Wegovy vs Saxenda page covers that comparison if it is relevant to you.

If you are wondering whether semaglutide or tirzepatide is the better fit for your situation, that is precisely the kind of question our prescribers work through with you at consultation. NICE's appraisal of tirzepatide (TA1026) sets out the clinical eligibility criteria; Wegovy is governed by NICE TA875. Both are prescription-only medicines, and eligibility depends on your full clinical picture, not just your BMI.

Neither Wegovy nor Mounjaro is something you can obtain legitimately without a prescription. Sellers offering either medicine without one (sometimes with a discount code thrown in as reassurance) are a red flag. Counterfeit semaglutide and tirzepatide pens have been seized in large quantities by the MHRA; some contained entirely different substances. Checking that any online pharmacy you use appears on the GPhC register takes about thirty seconds and is worth doing. nume's GPhC premises registration is 9012878.

Which is the right choice for you, and how that decision gets made

The short answer: a prescriber decides, not a comparison article. People ask whether Wegovy is better than Ozempic partly because Ozempic became far more culturally visible, it was on the news, in celebrity interviews, everywhere during 2023 and 2024. Wegovy, despite being the licensed weight-management product, was quieter. That visibility gap created a false impression that Ozempic was the stronger or more effective option.

For weight management specifically, Wegovy at 2.4mg is the medicine with the correct UK licence, the randomised trial data at that dose, and the NICE recommendation. If you are curious about cost context for the licensed options, our Wegovy pricing page explains what UK private treatment typically involves. And if you want to understand how the consultation works before committing to anything, our FAQs cover the process clearly.

Whether semaglutide via Wegovy or tirzepatide via Mounjaro is better suited to you depends on your medical history, current conditions, any other medicines you take, and your preferences around injection frequency and formulation. Some people do well on one and not the other. That conversation happens at consultation. Which suits you is a clinical decision our prescribers make with you, check your eligibility and start your free consultation here.